Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib
Lung Cancer Management
doi 10.2217/lmt-2019-0011
Full Text
Open PDFAbstract
Available in full text
Date
March 4, 2020
Authors
Publisher
Future Medicine Ltd